Bendcare Supports aiSLE™ DX Flare Risk Index Testing Access for Patients with Lupus (SLE)

OKLAHOMA CITY, April 8, 2021 /PRNewswire/ — Progentec, a leader in diagnostic and digital technologies for the proactive management of autoimmune diseases, announced today that Bendcare, a large healthcare services and technology organization which empowers community rheumatologists in the United States, is supporting clinician and patient access to the aiSLE™ DX Flare Risk Index. Bendcare plans to begin offering rheumatologists in the Bendcare and American Arthritis and Rheumatology Associates (AARA) networks clinical education sessions focused on the laboratory technology later this month. Additionally, Progentec will be utilizing Bendcare’s Columbus Data Repository to analyze the impact of the aiSLE™ DX Flare Risk Index.

“aiSLE™ DX Flare Risk Index represents a paradigm shift in the treatment of lupus (SLE) patients. Proteomics empowers clinicians to treat lupus patients based on changes in the underlying immunology,” said Mohan Purushothaman, Ph.D., Chairman and CEO of Progentec. “aiSLE™ DX Flare Risk Index calculates a patient’s future risk of a lupus flare. Early identification of SLE flares provides an additional tool in the hands of the clinicians to help them take proactive steps to mitigate irreversible damage caused by the disease. This damage ultimately leads to morbidity, mortality, and increased resource utilization.”

Systemic lupus erythematosus (“SLE” or “lupus”) is an extremely challenging disease to manage clinically. It has become a top 20 leading cause of death for young American women and disproportionately affects Black, Indigenous, and People of Color (BIPOC) communities. Challenges in achieving positive lupus health outcomes stem from the complex underlying biology of the autoimmune disease and the impact of social determinants of health (SDOH), specifically access to care and health literacy.

Learn more about using aiSLE™ DX Flare Risk Index and Progentec’s other technologies at: https://progentec.com

About Progentec Diagnostics, Inc.
Progentec is committed to improving access and health outcomes for patients with autoimmune diseases by combining clinically validated diagnostic interventions with state-of-the-art digital technologies. Through collaborations with research institutions and health practitioners around the world, Progentec is working to reduce mortality and morbidity while improving care management and service delivery for chronic health conditions.

About Bendcare, LLC
Bendcare, LLC (www.bendcare.com) provides services, technology, education, and purchase power solutions to specialty providers and patients on journey. They strive to create healthier healthcare by returning control to physicians and patients, improving  quality and outcomes while creating cost-effective care in a community-practice setting.

Bendcare’s proprietary Columbus data repository delivers real-time access and real world evidence (RWE) for research, value-based reimbursement, practice performance monitoring, and patient treatment decision support. Columbus’ unique visualization and proprietary patient engagement software facilitates intelligent collection and targeted educational campaigns through its web and app platforms.

Forward-Looking Statements:

Statements contained herein that are not historical facts are forward-looking statements that represent management’s beliefs and assumptions as of the date of this news release based on currently available information. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it cannot assure that these expectations will prove to be correct. Such statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements.

Contact: Brett Adelman
(405) 216-4818, Ext. 105
badelman@progentec.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/bendcare-supports-aisle-dx-flare-risk-index-testing-access-for-patients-with-lupus-sle-301265269.html

SOURCE Progentec Diagnostics, Inc.